India’s Jubilant, Eli Lilly In Joint Venture To Develop Molecules
This article was originally published in PharmAsia News
Executive Summary
Jubilant Organosys of India and Eli Lilly created a joint venture to develop molecules to develop a variety of treatments, including cancer and diabetes. The evenly divided research and development venture intends to develop molecules through the Phase II stage as well as develop molecules for other pharmaceutical companies. The new company is to be based in India and begin operating before the end of the year, with the parent companies investing a combined $8 million over the next three years. (Click here for more